Radiopharm Theranostics Limited · ASX:RAD

Radiopharm Theranostics — Investor Presentation (June 2022)

15 slides from Radiopharm Theranostics's investor presentation, Jun 9, 2022

  1. Slide 1: Establishing a new platform in the sector with glioblastoma targeting agent

    For personal use only Establishing a new platform in the sector with GLIOBLASTOMA TARGETING AGENT FOR DIAGNOSTIC IMAGING AND RADIOPHARMACEUTICAL THERAPY FROM CASE WESTERN RESERVE UNIVERSITY June 2022 Riccardo Canevari CEO, Radiopharm Theranostics Ltd

  2. Slide 2: Disclaimer

    DISCLAIMER For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in RadioPharm Theranostics Ltd AC

  3. Slide 3: Investment Highlights

    INVESTMENT HIGHLIGHTS  Sublicensing of promising imaging & therapeutic radiopharmaceutical from leading US university, Case For personal use only Western Reserve University, Ohio  PTPµ (PTPmu) fragment, the target, is a unique biomarker, present only in tumor cells but NOT in healthy tissues  Enc

  4. Slide 4: The Technology and MoA

    THE TECHNOLOGY AND MoA For personal use only The cell surface receptor PTPµ is specifically cleaved The PTPµ biomarker is present in multiple tumor on tumor cells, but NOT normal cells, creating a types including brain tumors and gynecological unique biomarker present only in the tumor cell cancer.

  5. Slide 5: Inventor & Institution

    INVENTOR & INSTITUTION For personal use only Dr. Susann Brady-Kalnay, PhD Dr. Brady-Kalnay is a professor and distinguished faculty researcher in the Case Western Reserve University School of Medicine is at department of Molecular Biology & the forefront of medical education, dedicated to enhancing

  6. Slide 6: Preclinical Data – The Target

    PRECLINICAL DATA – THE TARGET For personal use only PTPµ SBK2-Tumor-specific Molecular Targeting Agent S-S • PTPµ extracellular fragment as a Receptor in S-S recognition site on dispersing tumor cells healthy (normal) Fragment in cells tumor cells RADIOPHARM THERANOSTICS LTD 2022 |5

  7. Slide 7: Preclinical Data: agent detects tumor cells but not normal cells

    PRECLINICAL DATA PTPµ-targeted agent detects tumor cells but not normal cells For personal use only Phase PTPµ Agent Phase PTPµ Agent “Normal” Human Brain / Epilepsy Adult Glioblastoma Burden-Gulley et al 2010 PTPµ Agent FLUOROPHORE BRIGHTFIELD GFP/TUMOR PTPµ Agent OVERLAY XENOGRAFT MOUSE Craig et a

  8. Slide 8: Preclinical Data - Human GB Tumor Model

    PRECLINICAL DATA - HUMAN GB TUMOR MODEL PTPµ-targeted agent detects glioma in a flank tumor model in vivo For personal use only A Before tx 2 min 20 min 180 min GFP SBK2 B C 350 300 250 200 Normalized Signal SBK1-TR SBK2-AL 150 SBK3-TR SBK4-TR Scrambled D 100 SBK2 50 0 0 5 10 15 20 30 40 50 60 75 90

  9. Slide 9: Preclinical Data – Intracranial glioma tumors in vivo

    PRECLINICAL DATA – HUMAN GB TUMOR MODEL PTPµ-targeted agent detects intracranial glioma tumors in vivo For personal use only 2D Zoom Blood Vessels & Cy5 Co-label with Cy5 Overlay Anatomy Overlay Dispersing Cells Dispersing Cells Zoom A B C D E Example 1 F G H I J Example 2 Burden-Gulley et al 2013 R

  10. Slide 10: Clinical Development Plan: Overview

    CLINICAL DEVELOPMENT PLAN: OVERVIEW For personal use only PTPµ biomarker present in multiple tumor types Brain and other tumor types High unmet medical need First Indication Selected: Orphan indication (fast regulatory process) GLIOBLASTOMA No approved radiopharmaceutical therapy Phase I: Adults wit

  11. Slide 11: Glioblastoma

    GLIOBLASTOMA For personal use only  Highly invasive, treatment- resistant cancer Patient with initial symptoms  5-year survival rate is 6.8% SCAN  Only four drugs and one device approved by the FDA for SURGERY treatment RADIATION & CHEMOTHERAPY  Invasive cells left behind after surgical resectio

  12. Slide 12: Market & Competition

    MARKET & COMPETITION For personal use only KEY STATISTICS FOR DIAGNOSTIC OPTIONS COMPETITION GLIOBLASTMA Average length of survival is 14 months No targeted diagnostic imaging Nonspecific MRI from diagnosis agents for Glioblastoma No targeted radiopharmaceutical Each year, 13,500 new cases are FDG P

  13. Slide 13: Manufacturing & IP

    MANUFACTURING & IP For personal use only Manufacturing IP San Diego, CA USA  US Patents: 8,686,112 B2; 9,415,122 B2; 10,238,757  US Applications: 16/365,166; 16/608,021; and 63/062,053  International Applications: PCT/US21/53867; EPO 18791941.0  Expected loss of exclusivity January 2037 RADIOPHA

  14. Slide 14: Summary

    SUMMARY For personal use only  Radiopharmaceutical therapy potential, in-licensed by leading institution (CWRU)  Targeting PTPµ tumor specific fragment, present in multiple tumor types  Rapid Blood Brain Barrier Penetration  High Tumor Sensitivity and Specificity  Rapid Orphan Disease, Fast Tra

  15. Slide 15: Contact Us

    For personal use only CONTACT US Ricardo Canevari Paul Hopper CEO & MANAGING DIRECTOR Executive Chairman Radiopharm Theranostics Limited Radiopharm Theranostics Limited T +1 862 309 0293 T +61 406 671 515 E rc@radiopharmtheranostic.com E paulhopper@lifescienceportfolio.com W www.radiopharmtheranosti

Radiopharm Theranostics — Investor Presentation (June 2022) on 6ix